Skip to main content

What Happened to the Winklevii After Facebook

Readers of 2009's The Accidental Billionaires (and viewers of the film adaptation, The Social Network) might have thought that Tyler and Cameron Winklevoss got short shrift--both in what happened at Facebook and in having a smaller slice of the narrative. Now author Ben Mezrich is back to give the entrepreneurial twins the lead roles in a new book, Bitcoin Billionaires: A True Story of Genius, Betrayal, and Redemption (Flatiron Books), tracing their lives and work since the late-aughts' legal battle with Mark Zuckerberg. Cryptocurrency followers should already be familiar with the pair's digital currency fund as Bitcoin has blown up and gone haywire in recent years. But Mezrich's account of their past decade is gripping from the opening pages, potentially setting the twins up for yet another portrayal by Hollywood.

A version of this article appears in the May 2019 issue of Fortune with the headline “After Zuck: The Winklevii’s Next Chapter.”



from Fortune http://bit.ly/2J6T3v4
Labels:

Comments

Post a Comment

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $
Post a Comment
Read more

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be
Post a Comment
Read more